Aptinyx Advances NMDA Receptor Modulators To Ease Pain
• By Mike Ward
In the two years since Aptinyx was spun-out from predecessor Naurex, the US biotech has gone from being a preclinical company to one with two Phase II programs and a third to enter that stage in 3Q 2018. Company president and CEO, Norbert Riedel met up with Scrip at the 2018 Biotech Showcase and revealed how Aptinyx intends to spend the $70m it raised in a series B financing late last year.
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.